Premium Company Profile - Pain Therapeutics
Premium Company Profile - Pain Therapeutics - New Research Report on Companies and Markets
© companiesandmarkets.com
15.11.2008 00:40:02 www.companiesandmarkets.com adds new report - Premium Company Profile - Pain Therapeutics
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
Pain Therapeutics was initially focused on building a franchise of pain management products through partnering with the scientific and medical community. In 2006, Pain Therapeutics changed its focus from being a clinical research based company to becoming a fully integrated biopharmaceutical franchise through in-licensing activities.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial
trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Pain Therapeutics is focused on the development and commercialization of pharmaceutical products for pain management and hematology/oncology indications. The company has three investigational drug candidates in clinical programs, namely, Remoxy and PTI-202 which are in the Phase III and Phase I stage respectively.
Pain Therapeutics derives its revenues mainly from program fee and collaboration related to the strategic alliance with King Pharmaceuticals for the development and commercialization of Remoxy and other abuse-resistant opioid painkillers.
The company´s total revenues increased significantly during the fiscal year 2006, from $5 million in 2005 to $54 million in 2006 The company´s major contributor to the revenues during 2006 was program fee related to the strategic alliance with King Pharmaceuticals, which recorded revenues of $26 million during 2006.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
Introduction
Pain Therapeutics was initially focused on building a franchise of pain management products through partnering with the scientific and medical community. In 2006, Pain Therapeutics changed its focus from being a clinical research based company to becoming a fully integrated biopharmaceutical franchise through in-licensing activities.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial
|
|
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Pain Therapeutics is focused on the development and commercialization of pharmaceutical products for pain management and hematology/oncology indications. The company has three investigational drug candidates in clinical programs, namely, Remoxy and PTI-202 which are in the Phase III and Phase I stage respectively.
Pain Therapeutics derives its revenues mainly from program fee and collaboration related to the strategic alliance with King Pharmaceuticals for the development and commercialization of Remoxy and other abuse-resistant opioid painkillers.
The company´s total revenues increased significantly during the fiscal year 2006, from $5 million in 2005 to $54 million in 2006 The company´s major contributor to the revenues during 2006 was program fee related to the strategic alliance with King Pharmaceuticals, which recorded revenues of $26 million during 2006.
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
| Author: |
